Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease

Pamela Ely, Jordan Dunitz, John Rogosheske, Daniel Weisdorf

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Purpose: Because the secretory diarrhea of acute graft-versus-host disease (GvHD) of the gut induces serious metabolic and nutritional disturbances, this study was initiated to assess the use of a somatostatin analogue, octreotide acetate, as adjunctive therapy for severe GvHD of the gut with massive diarrhea. Patients and methods: In a pilot study, six patients with biopsy-confirmed acute gut GvHD after allogeneic bone marrow transplantation received octreotide 50 to 250 μg three times a day subcutaneously. Results: Three of the six treated patients had a prompt and dramatic reduction in stool volume within 1 to 3 days of initiation of octreotide therapy. Conclusions: Somatostatin and its analogues have been used successfully in diarrheal states by antagonism of neuropeptide overproduction, although other potential therapeutic mechanisms include inhibition of fluid secretion, enhanced salt absorption, and inhibition of gut motility. Somatostatin and its analogues may be promising adjunctive agents in the treatment of gastrointestinal GvHD, although assessment in a controlled trial will be required to confirm their therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)707-710
Number of pages4
JournalThe American Journal of Medicine
Volume90
Issue number6
DOIs
StatePublished - Jun 1991

Fingerprint Dive into the research topics of 'Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease'. Together they form a unique fingerprint.

Cite this